Latest Breaking News On - Adrian gottschalk - Page 6 : comparemela.com

Foghorn Therapeutics Inc (FHTX) Announces Board Changes

Foghorn Therapeutics Inc (FHTX) Announces Board Changes
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

Cigall kadochDouglas coleAdrian gottschalkTherapeutics incFoghorn coHoward hughes medical institute investigatorInvestigator for the howard hughes medical instituteHoward hughes medical instituteScientific advisorScientific advisoryFlagship pioneering managing partnerFoghorn co founder

FDA Places Full Hold on Foghorn s Phase I Study in Relapsed/Refractory AML/MDS

FDA Places Full Hold on Foghorn s Phase I Study in Relapsed/Refractory AML/MDS
globalgenes.org - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from globalgenes.org Daily Mail and Mail on Sunday newspapers.

United statesAdrian gottschalkDrug administrationFoghorn therapeuticGene traffic control

Foghorn Therapeutics Inc (FHTX) Elects Lynne Parshall to its Board

Foghorn Therapeutics Inc (FHTX) Elects Lynne Parshall to its Board
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

United statesDoug coleAdrian gottschalkB lynne parshallStanford law schoolSenior strategic advisor for ionis pharmaceuticalsTherapeutics incFoghorn coHarvard universityAudit committeeSenior strategic advisorRepertoire immune medicinesCalifornia barStanford lawFlagship pioneering managing partnerFoghorn co founder

Foghorn Therapeutics Provides Second Quarter 2022 Financial and Corporate Update

09.08.2022 - - FHD-286 dose escalation Phase 1 study in metastatic uveal melanoma continues to progress per protocol; working to resolve partial clinical hold in AML and MDS - On track to report initial Phase 1 clinical data for FHD-609 in synovial .

United statesUnited kingdomKarin hellsvikMichael lampeAdrian gottschalkHans vitzthumFoghorn therapeutics incDrug administrationCompany annual report on formDevelopment expensesExchange commissionTherapeutics incGene traffic control platformBalance sheetLilly collaboration agreementGene traffic control

Foghorn Therapeutics : Provides Second Quarter 2022 Financial and Corporate Update - Form 8-K

Foghorn Therapeutics Provides Second Quarter 2022 Financial and Corporate Update -FHD-286 dose escalation Phase 1 study in metastatic uveal melanoma continues. | August 9, 2022

United statesUnited kingdomKarin hellsvikMichael lampeAdrian gottschalkHans vitzthumFoghorn therapeutics incDrug administrationExchange commissionCompany annual report on formDevelopment expensesTherapeutics incFoghorn therapeutics provides second quarterCorporate updateGene traffic controlMerck collaboration